Effects of subcutaneous esketamine on blood pressure and heart rate in treatment-resistant depression.
Lorena Catarina Del SantLuciana Maria SarinEduardo Jorge Muniz MagalhãesAna Cecília LuccheseMarco Aurélio TuenaCarolina NakahiraVictor Augusto Rodovalho FavaRodrigo DelfinoJuliana SurjanMatheus Souza SteiglichMatheus BarbosaGuilherme AbdoFrederico Molina CohrsAroldo LiberatoriJosé Alberto Del PortoAcioly Luiz Tavares LacerdaJair de Jesus MariPublished in: Journal of psychopharmacology (Oxford, England) (2020)
The BP changes observed with repeated s.c. esketamine injections were mild and well tolerated for doses up to 1 mg/kg. The s.c. route is a simple and safe method of esketamine administration, even for patients with clinical comorbidities, including obesity, hypertension, diabetes, and dyslipidemia. However, 14/70 patients experienced treatment-emergent transient hypertension (SBP >180 mmHg and/or a DBP >110 mmHg). Therefore, we strongly recommend monitoring BP for 90 minutes after esketamine dosing. Since s.c. esketamine is cheap, requires less frequent dosing (once a week), and is a simpler procedure compared to intravenous infusions, it might have an impact on public health.
Keyphrases
- blood pressure
- heart rate
- public health
- heart rate variability
- hypertensive patients
- end stage renal disease
- type diabetes
- chronic kidney disease
- newly diagnosed
- metabolic syndrome
- ejection fraction
- cardiovascular disease
- prognostic factors
- insulin resistance
- depressive symptoms
- weight loss
- peritoneal dialysis
- clinical trial
- minimally invasive
- randomized controlled trial
- high dose
- body mass index
- skeletal muscle
- low dose
- physical activity
- weight gain
- combination therapy
- smoking cessation
- brain injury
- high fat diet induced